Bristol-Myers Squibb
Market Cap
US$150.8b
Last Updated
2021/01/19 23:24 UTC
Data Sources
Company Financials +
Executive Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential average dividend payer.
Similar Companies
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
2.0%
BMY
2.4%
US Pharmaceuticals
0.3%
US Market
1 Year Return
-1.0%
BMY
4.8%
US Pharmaceuticals
21.1%
US Market
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: BMY underperformed the US Market which returned 19.5% over the past year.
Shareholder returns
| BMY | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.0% | 2.4% | 0.3% |
| 30 Day | 5.7% | 5.8% | 3.3% |
| 90 Day | 11.2% | 13.0% | 14.2% |
| 1 Year | 2.1%-1.0% | 8.4%4.8% | 23.8%21.1% |
| 3 Year | 15.4%5.2% | 25.4%15.7% | 45.0%35.4% |
| 5 Year | 22.9%6.5% | 53.3%35.1% | 127.7%102.3% |
Long-Term Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Don't Race Out To Buy Bristol-Myers Squibb Company (NYSE:BMY) Just Because It's Going Ex-Dividend1 month ago | Simply Wall St
What Does Bristol-Myers Squibb's (NYSE:BMY) CEO Pay Reveal?1 month ago | Simply Wall St
Have Insiders Been Selling Bristol-Myers Squibb Company (NYSE:BMY) Shares?Valuation
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($66.74) is trading below our estimate of fair value ($149.81)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: BMY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMY is good value based on its PB Ratio (3x) compared to the US Pharmaceuticals industry average (4.4x).
Next Steps
Future Growth
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
91.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMY's is expected to become profitable in the next 3 years.
Revenue vs Market: BMY's revenue (3.9% per year) is forecast to grow slower than the US market (10.3% per year).
High Growth Revenue: BMY's revenue (3.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be very high in 3 years time (42.6%).
Next Steps
Past Performance
How has Bristol-Myers Squibb performed over the past 5 years?
-3.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMY is currently unprofitable.
Growing Profit Margin: BMY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMY is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: BMY has a negative Return on Equity (-0.056%), as it is currently unprofitable.
Next Steps
Financial Health
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($34.3B) exceed its short term liabilities ($20.5B).
Long Term Liabilities: BMY's short term assets ($34.3B) do not cover its long term liabilities ($54.8B).
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (89.5%) is considered high.
Reducing Debt: BMY's debt to equity ratio has increased from 47.7% to 89.5% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (27.6%).
Interest Coverage: BMY is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Bristol-Myers Squibb current dividend yield, its reliability and sustainability?
2.94%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BMY's dividend (2.94%) is higher than the bottom 25% of dividend payers in the US market (1.39%).
High Dividend: BMY's dividend (2.94%) is low compared to the top 25% of dividend payers in the US market (3.85%).
Stability and Growth of Payments
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BMY is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (25.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.5yrs
Average management tenure
CEO
Giovanni Caforio (55 yo)
5.67yrs
Tenure
US$18,767,253
Compensation
Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...
CEO Compensation Analysis
Compensation vs Market: Giovanni's total compensation ($USD18.77M) is above average for companies of similar size in the US market ($USD10.55M).
Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5.67yrs | US$18.77m | 0.020% $ 29.7m | |
| Executive VP & CFO | 1.17yrs | US$5.49m | 0.0030% $ 4.5m | |
| Executive VP & General Counsel | 13.92yrs | US$7.52m | 0.019% $ 29.3m | |
| Executive VP & Chief Commercialization Officer | 3yrs | US$5.74m | 0.00099% $ 1.5m | |
| Executive VP and President of Research & Early Development | 1.17yrs | US$5.17m | no data | |
| Executive VP & Chief Information Officer | 9yrs | no data | 0.0056% $ 8.5m | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Senior VP | 3yrs | no data | 0.00071% $ 1.1m | |
| Executive VP & Chief Human Resources Officer | 4.58yrs | no data | 0.0023% $ 3.4m | |
| Executive VP and President of Global Product Development & Supply | 3.75yrs | US$4.13m | 0.0012% $ 1.8m | |
| Head of US Drug Makers - India | 6.5yrs | no data | no data | |
| Head of Oncology Development | 4.5yrs | no data | no data |
4.5yrs
Average Tenure
55yo
Average Age
Experienced Management: BMY's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5.67yrs | US$18.77m | 0.020% $ 29.7m | |
| Independent Director | 1.17yrs | US$48.41k | 0.00047% $ 708.8k | |
| Independent Director | 9yrs | US$315.00k | no data | |
| Lead Independent Director | 3.67yrs | US$393.24k | no data | |
| Independent Director | 7.5yrs | US$353.85k | 0.00098% $ 1.5m | |
| Independent Director | 3.92yrs | US$354.81k | 0.000010% $ 15.1k | |
| Independent Director | 1.17yrs | US$78.41k | no data | |
| Independent Director | 3.92yrs | US$332.50k | 0.00050% $ 754.1k | |
| Independent Director | 4.75yrs | US$354.81k | no data | |
| Independent Director | 3.92yrs | US$337.50k | 0.0012% $ 1.8m | |
| Independent Director | 1.17yrs | US$78.41k | 0.00030% $ 452.4k | |
| Independent Director | 3yrs | US$335.17k | no data |
3.9yrs
Average Tenure
63yo
Average Age
Experienced Board: BMY's board of directors are considered experienced (3.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BMY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$150.816b
- Shares outstanding: 2.26b
- Website: https://www.bms.com
Number of Employees
Location
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- 10016
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMY | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1968 |
| BMY * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1968 |
| BRM | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BRM | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BMY | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1968 |
| 0R1F | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1968 |
| BRM | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jan 1968 |
| BMYS | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1968 |
| BMY | BVL (Bolsa de Valores de Lima) | Yes | Common Stock | PE | USD | Jan 1968 |
| BMY | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 3 REP 1 | AR | ARS | Mar 2009 | |
| BMYB34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EA REPR 1 COM SHS | BR | BRL | Aug 2012 |
Biography
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therap...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/19 23:24 |
| End of Day Share Price | 2021/01/19 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.